Acipimox

Product introduction:

Acipimox is a nicotinic acid derivative. It can inhibit the release of free fatty acids from adipose tissue; Reduce very low density lipoprotein (VLDL) and low density lipoprotein in blood, so as to reduce the concentration of triglyceride (TG) and cholesterol (CH) in blood. It can also promote the increase of high density lipoprotein (HDL) and HDL metabolism of lipids in blood.

CAS：51037-30-0

Molecular formula: C₆H₆N₂O₃

Molecular weight: 154.12

Structure:

Product purpose:

1. It acts on the liver and adipose tissue and inhibits the lipolysis of adipose tissue, so as to reduce plasma total cholesterol, triglyceride, low-density lipoprotein and very low-density lipoprotein.

2. Increase HDL in plasma, which is conducive to cholesterol transport and clearance.

3. Increase liver glycogen synthesis and reduce blood glucose level. This drug can be used as the first choice of lipid-lowering drugs for various hyperlipidemia, especially for diabetic patients with hyperlipidemia.